162 related articles for article (PubMed ID: 27021931)
1. The Cambridge Breast Intensity-modulated Radiotherapy Trial: Comparison of Clinician- versus Patient-reported Outcomes.
Mukesh MB; Qian W; Wah Hak CC; Wilkinson JS; Barnett GC; Moody AM; Wilson C; Coles CE
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):354-64. PubMed ID: 27021931
[TBL] [Abstract][Full Text] [Related]
2. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial.
Mukesh MB; Qian W; Wilkinson JS; Dorling L; Barnett GC; Moody AM; Wilson C; Twyman N; Burnet NG; Wishart GC; Coles CE
Radiother Oncol; 2014 May; 111(2):270-5. PubMed ID: 24746570
[TBL] [Abstract][Full Text] [Related]
3. Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up.
Brouwers PJAM; van Loon J; Houben RMA; Paulissen J; Engelen SME; Heuts M; de Boer M; Verhoeven K; De Ruysscher D; Boersma LJ
Radiother Oncol; 2018 Jan; 126(1):163-169. PubMed ID: 28844787
[TBL] [Abstract][Full Text] [Related]
4. The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity.
Barnett GC; Wilkinson JS; Moody AM; Wilson CB; Twyman N; Wishart GC; Burnet NG; Coles CE
Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):662-73. PubMed ID: 21646002
[TBL] [Abstract][Full Text] [Related]
5. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.
Shaitelman SF; Schlembach PJ; Arzu I; Ballo M; Bloom ES; Buchholz D; Chronowski GM; Dvorak T; Grade E; Hoffman KE; Kelly P; Ludwig M; Perkins GH; Reed V; Shah S; Stauder MC; Strom EA; Tereffe W; Woodward WA; Ensor J; Baumann D; Thompson AM; Amaya D; Davis T; Guerra W; Hamblin L; Hortobagyi G; Hunt KK; Buchholz TA; Smith BD
JAMA Oncol; 2015 Oct; 1(7):931-41. PubMed ID: 26247543
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated whole-breast radiation therapy: does breast size matter?
Hannan R; Thompson RF; Chen Y; Bernstein K; Kabarriti R; Skinner W; Chen CC; Landau E; Miller E; Spierer M; Hong L; Kalnicki S
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):894-901. PubMed ID: 22543209
[TBL] [Abstract][Full Text] [Related]
7. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial.
Bhattacharya IS; Haviland JS; Hopwood P; Coles CE; Yarnold JR; Bliss JM; Kirby AM;
Radiother Oncol; 2019 May; 134():220-230. PubMed ID: 31005219
[TBL] [Abstract][Full Text] [Related]
8. Impact of hypofractionation and tangential beam IMRT on the acute skin reaction in adjuvant breast cancer radiotherapy.
Rudat V; Nour A; Ghaida SA; Alaradi A
Radiat Oncol; 2016 Jul; 11():100. PubMed ID: 27473272
[TBL] [Abstract][Full Text] [Related]
9. Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
Haviland JS; Hopwood P; Mills J; Sydenham M; Bliss JM; Yarnold JR;
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):345-353. PubMed ID: 26868286
[TBL] [Abstract][Full Text] [Related]
10. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
Freedman GM; Anderson PR; Goldstein LJ; Ma CM; Li J; Swaby RF; Litwin S; Watkins-Bruner D; Sigurdson ER; Morrow M
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):347-53. PubMed ID: 17379430
[TBL] [Abstract][Full Text] [Related]
11. Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer.
Christodoulou M; McCloskey P; Stones N; Bayman N; Burt P; Chittalia A; Harris M; Lee L; Pemberton L; Sheikh H; Swindell R; Faivre-Finn C
Radiother Oncol; 2014 Aug; 112(2):244-9. PubMed ID: 25107555
[TBL] [Abstract][Full Text] [Related]
12. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost.
McDonald MW; Godette KD; Whitaker DJ; Davis LW; Johnstone PA
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):523-30. PubMed ID: 19775834
[TBL] [Abstract][Full Text] [Related]
13. [Dosimetric evaluation of intensity-modulated tangential beam versus conventional tangential irradiation for breast cancer].
Huang XB; Jiang GL; Chen JY; Chen LF; Hu WG
Ai Zheng; 2006 Jul; 25(7):855-60. PubMed ID: 16831277
[TBL] [Abstract][Full Text] [Related]
14. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
Barnett GC; Coles CE; Elliott RM; Baynes C; Luccarini C; Conroy D; Wilkinson JS; Tyrer J; Misra V; Platte R; Gulliford SL; Sydes MR; Hall E; Bentzen SM; Dearnaley DP; Burnet NG; Pharoah PD; Dunning AM; West CM
Lancet Oncol; 2012 Jan; 13(1):65-77. PubMed ID: 22169268
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers.
Horton JK; Blitzblau RC; Yoo S; Geradts J; Chang Z; Baker JA; Georgiade GS; Chen W; Siamakpour-Reihani S; Wang C; Broadwater G; Groth J; Palta M; Dewhirst M; Barry WT; Duffy EA; Chi JT; Hwang ES
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):846-55. PubMed ID: 26104938
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya IS; Haviland JS; Kirby AM; Kirwan CC; Hopwood P; Yarnold JR; Bliss JM; Coles CE;
J Clin Oncol; 2019 Feb; 37(4):305-317. PubMed ID: 30532984
[TBL] [Abstract][Full Text] [Related]
17. Hyperbaric oxygen therapy for late radiation-induced tissue toxicity: prospectively patient-reported outcome measures in breast cancer patients.
Teguh DN; Bol Raap R; Struikmans H; Verhoef C; Koppert LB; Koole A; Huang Y; van Hulst RA
Radiat Oncol; 2016 Sep; 11(1):130. PubMed ID: 27682427
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy.
Chen CC; Wang L; Lu CH; Lin JC; Jan JS
J Formos Med Assoc; 2014 Dec; 113(12):949-55. PubMed ID: 24144528
[TBL] [Abstract][Full Text] [Related]
19. Proposal for a gold standard for cosmetic evaluation after breast conserving therapy: Results from the St George and Wollongong Breast Boost trial.
Merie R; Browne L; Cardoso JS; Cardoso MJ; Chin Y; Clark C; Graham P; Szwajcer A; Hau E
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):819-825. PubMed ID: 28834326
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Long-term Cosmetic Outcomes Following Short Fractionation Whole Breast Radiotherapy With Boost.
Chan EK; Tabarsi N; Tyldesley S; Khan M; Woods R; Speers C; Weir L
Am J Clin Oncol; 2016 Oct; 39(5):473-8. PubMed ID: 24824143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
